Tirzepatide's potential cardioprotective effects in patients with type 2 diabetes are evaluated based on insights from the SURPASS-CVOT trial.
Absolute Event Rate: 0% vs 0%
The authors have nothing to report. The authors declare no conflicts of interest. Data availability is not applicable for this manuscript. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.70766.
“The take-home message is that this validates the cardiovascular benefit of tirzepatide. We now have more evidence to use this agent in a range of clinical settings and, importantly, our patients have greater choice. What we now need to do is translate these benefits into better access: we have the tools to help our patients [so] we just need to make sure they have access to use them.”
Cosentino et al. (Wed,) reported a other. Tirzepatide's potential cardioprotective effects in patients with type 2 diabetes are evaluated based on insights from the SURPASS-CVOT trial.